Clinical Trial Update: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating adjunctive low-dose metformin in patients with schizophrenia and metabolic abnormalities (metabolic syndrome) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Schizophrenia

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Taipei Medical University WanFang Hospital | Conditions: Metabolic Syndrome | Phase 4 | Status: COMPLETED